Esperion Therapeutics (ESPR) Non-Current Deffered Revenue (2019 - 2022)

Esperion Therapeutics' Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $211000.0 for Q2 2022.

• Quarterly Non-Current Deffered Revenue fell 80.04% year-over-year to $211000.0 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $211000.0 (down 80.04% YoY) and the FY2021 annual result came in at $634000.0, changed N/A from the prior year.
• Non-Current Deffered Revenue was $211000.0 for Q2 2022 at Esperion Therapeutics, down from $422000.0 in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $1.1 million in Q2 2021 and bottomed at $211000.0 in Q2 2022.
• A 3-year average of $637333.3 and a median of $644500.0 in 2019 frame the typical range for Non-Current Deffered Revenue.
• Peak annual rise in Non-Current Deffered Revenue reached 80.04% in 2022, while the deepest fall reached 80.04% in 2022.
• Esperion Therapeutics' Non-Current Deffered Revenue stood at $655000.0 in 2019, then slipped by 3.21% to $634000.0 in 2021, then sank by 66.72% to $211000.0 in 2022.
• Business Quant data shows ESPR's Non-Current Deffered Revenue at $211000.0 in Q2 2022, $422000.0 in Q1 2022, and $634000.0 in Q4 2021.